Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy

Molecular Imaging and Biology

Volumn 13, Issue 2, 2011, Pages 215-221

  Orcutt, Kelly Davis ^a   Nasr, Khaled A ^c   Whitehead, David G ^c   Frangioni, John V ^c   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Biodistribution; Clearance; DOTA; Pretargeted radioimmunotherapy; Radiation dosimetry

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANILINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIOTIN 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CD1 ANTIGEN; IODINE 131; LUTETIUM 177; TYROSINE LYSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; UNCLASSIFIED DRUG; YTTRIUM 90;

ANATOMICAL VARIATION; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BONE MARROW; CONTROLLED STUDY; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY;

ANIMALS; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HAPTENS; INJECTIONS, INTRAVENOUS; MALE; MICE; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

MUS;

EID: 79955934218     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0353-6     Document Type: Article

References (37)

1. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44:400-411 (Pubitemid 39586017)
2. Gruaz-Guyon A, Raguin O, Barbet J (2005) Recent advances in pretargeted radioimmunotherapy. Curr Med Chem 12:319-338 (Pubitemid 40305623)
3. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W (1988) Pre-targeted immunoscintigraphy of murine tumors with indium- 111-labeled bifunctional haptens. J Nucl Med 29:226-234 (Pubitemid 18056734)
4. Axworthy DB, Reno JM, Hylarides MD et al (2000) Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 97:1802-1807 (Pubitemid 30118523)
5. Subbiah K, Hamlin DK, Pagel JM et al (2003) Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 44:437-445 (Pubitemid 39586022)
6. Pagel JM, Orgun N, Hamlin DK et al (2009) A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 113:4903-4913
7. Sharkey RM, Karacay H, Johnson CR et al (2009) Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med 50:444-453
8. Hamblett KJ, Kegley BB, Hamlin DK et al (2002) A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjug Chem 13:588-598 (Pubitemid 34527521)
9. Forster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM (2006) Pretargeted radioimmunotherapy with a single-chain antibody/ streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med 47:140-149 (Pubitemid 46768523)
10. Sharkey RM, McBride WJ, Karacay H et al (2003) A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 63:354-363 (Pubitemid 36152493)
11. Gautherot E, Rouvier E, Daniel L et al (2000) Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J Nucl Med 41:480-487 (Pubitemid 30133969)
12. Chen X, Park R, Tohme M et al (2004) MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 15:41-49 (Pubitemid 38165979)
13. Chen X, Sievers E, Hou Y et al (2005) Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 7:271-279 (Pubitemid 40411639)
14. Garrison JC, Rold TL, Sieckman GL et al (2007) In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 48:1327-1337
15. Zhang H, Schuhmacher J, Waser B et al (2007) DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 34:1198-1208 (Pubitemid 47296770)
16. Schmitt A, Bernhardt P, Nilsson O et al (2005) Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm 20:231-236 (Pubitemid 40696108)
17. Wild D, Behe M, Wicki A et al (2006) [Lys40(Ahx-DTPA-111In)NH2] exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 47:2025-2033
18. Haubner R, Wester HJ, Burkhart F et al (2001) Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42:326-336 (Pubitemid 32150525)
19. Ferreira CL, Lamsa E, Woods M et al (2010) Evaluation of bifunctional chelates for the development of gallium-based radiopharmaceuticals. Bioconjug Chem 21:531-536
20. Cutler CS, Smith CJ, Ehrhardt GJ et al (2000) Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm 15:531-545 (Pubitemid 32040942)
21. Le Mignon MM, Chambon C, Warrington S, Davies R, Bonnemain B (1990) Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol 25:933-937
22. Bourrinet P, Martel E, El Amrani AI et al (2007) Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol 42:63-77 (Pubitemid 46104886)
23. Orcutt KD, Ackerman ME, Cieslewicz M et al (2010) A modular IgGscFv bispecific antibody topology. Protein Eng Des Sel 23:221-228
24. Banerjee SR, Foss CA, Castanares M et al (2008) Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 51:4504-4517
25. Humblet V, Misra P, Frangioni JV (2006) An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives. Contrast Media Mol Imaging 1:196-211
26. Misra P, Humblet V, Pannier N, Maison W, Frangioni JV (2007) Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy. J Nucl Med 48:1379-1389 (Pubitemid 47242804)
27. Stabin MG, Siegel JA (2003) Physical models and dose factors for use in internal dose assessment. Health Phys 85:294-310 (Pubitemid 36999340)
28. Wessels BW, Bolch WE, Bouchet LG et al (2004) Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 45:1725-1733 (Pubitemid 47618483)
29. Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109-122
30. Barbet J, Peltier P, Bardet S et al (1998) Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEAxanti-DTPA-indium bispecific antibody. J Nucl Med 39:1172-1178 (Pubitemid 28326146)
31. Knox SJ, Goris ML, Tempero M et al (2000) Phase II trial of yttrium- 90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 6:406-414 (Pubitemid 30111457)
32. Lin Y, Pagel JM, Axworthy D et al (2006) A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. Cancer Res 66:3884-3892
33. Behr TM, Goldenberg DM, Becker W (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 25:201-212 (Pubitemid 28130048)
34. Kraeber-Bodere F, Rousseau C, Bodet-Milin C et al (2006) Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 47:247-255 (Pubitemid 46780889)
35. Fisher DR, Shen S, Meredith RF (2009) MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan. J Nucl Med 50:644-652
36. Zacchetti A, Coliva A, Luison E et al (2009) (177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol 36:759-770
37. Jaggi JS, Seshan SV, McDevitt MR et al (2006) Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys 64:1503-1512